The Role of Losartan in the Prevention of Early Structural Changes Associated With Radiation-Induced Heart Failure

22-457

This study is being done to see if losartan affects the chances of developing radiation-induced heart failure in patients who are receiving radiation therapy as part of standard of care treatment for breast cancer. The interventions involved in this study are: * Losartan * Radiation Therapy (standard of care)

2024-01-01

2024-10-01

2024-12-01

Recruiting

Early phase I

10

Inclusion Criteria: -\>18 years of age * Non-metastatic Breast Cancer patients who are scheduled to receive conventional left breast/chest wall RT inclusive of treatment to the internal mammary lymph nodes (IMNs) * Prior chemotherapy is permitted * Patients must have Left-sided Breast Cancer * Ability to understand and the willingness to sign a written informed consent document * No contraindication to MRI Exclusion Criteria: * Person who is pregnant or breastfeeding. * Patient unable to swallow oral medication. * Patients receiving any other investigational agent will not be excluded from study eligibility, unless the patient is already enrolled in an interventional study evaluating cardiac toxicity * Patients already receiving ACE/ARBs. * Patients with a history of allergic reactions to Losartan biosimilars.

{'studyType': 'INTERVENTIONAL', 'phases': ['EARLY_PHASE1'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 10, 'type': 'ESTIMATED'}}

2024-01-12